ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

vortosiran

Its studies are mostly in Atrial Fibrillation · Venous Thromboembolism, led by Suzhou Ribo Life Science.

Furthest: phase 2, since Sep 17, 20262 company-led studies, 2 open or runningNext primary completion: Jul 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Suzhou Ribo Life Science22 open or runningphase 2since Sep 17, 2026Sep 17, 2026Jul 2027phase 2 · NCT07850453

Also a collaborator on its studies: Link Medical Research AB and Fortrea.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Feb 13, 2025Named vortosiranINNProposed as its International Nonproprietary Name in WHO's List 132
  2. Sep 17, 2026First studies: 2 phase 2 studiesFirst studyNCT07850453, NCT07870889

Ahead

  1. Jul 2027Primary completion: phase 2 study in Venous ThromboembolismNCT07850453
  2. Jul 31, 2028Primary completion: phase 2 study in Atrial FibrillationNCT07870889

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07870889Atrial Fibrillation · Denmark, Norway, Poland and more2Not yet recruitingJul 31, 2028150
NCT07850453Venous Thromboembolism · Bulgaria, France, Poland and more2Not yet recruitingJul 2027150

How it is read

Names in the registry

  • “Vortosiran”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.